Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 116

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 116
---
 the damaged tissue in situations where
there is nothing holding them back or preventing them from migration, are unable to migrate due to the GelrinC implant and are controlled,
which allows for the receding implant to allow the surrounding cells to regenerate the cartilage in a controlled and synchronous process.
The body of this receding mass acts to stimulate the body’s natural healing process, by guiding the migration and organization of
cells involved in tissue repair doing so in a gradual process over time. Gelrin is applied in liquid form allowing it to completely fill
the entire tissue defect and is then cured into a rubbery implant by the use of ultraviolet, or UV, light. It can be introduced into narrow
bone crevices or large spaces, open or closed.

GelrinC is specifically designed
for the repair of articular cartilage defects in the knee caused by acute trauma or repetitive use. It is delivered directly to fill the
injury site using a delivery device, Stelar, which seals the lesion during the procedure, and through which the GelrinC liquid is delivered,
and from which the curing UV light is projected. Once the liquid GelrinC has filled the defect, it is cured in place into an elastomeric
implant by photo-curing under UV light for 90 seconds. The implant then starts eroding in conjunction with the advancing cartilage tissue
from the outside edges of the lesion inward. Following a period of approximately six to nine months, the implant is completely eroded,
resorbed and the injury’s surface is covered by newly formed hyaline-like cartilage produced by the patient’s own body. The
primary mode of action of GelrinC is presenting a smooth, impenetrable, neutral surface to the reproduced cartilage cells. The enabling
surface erosion completes this mechanism with a receding implant in a planned synchrony with the newly formed cartilage tissue.

<div align='center'>70</div>

Mode of Action of GelrinC:

| 1. Stelar delivery device membrane covers cartilage lesion. Using a syringe GelrinC is introduced into the lesion.                                                     |     | 2. Upon filing of the lesion, UV beam cures GelrinC into a soft rubbery implant.                                            |
| 3. As GelrinC implant recedes and resorbs, the cartilage lesion rim creates aggregates and new cartilage tissue filling up the void created by the retreating implant. |     | 4. At the end